Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23876895)

1.

MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission.

Liu S, Yuan YB, Guan LL, Wei H, Cheng Z, Han X, Yang L, Pu CC, Yang FD, Lu Z, Deng H, Zhao JP, Yu X.

Chin Med J (Engl). 2013 Jul;126(14):2676-80.

PMID:
23876895
2.

miR-520c-3p with therapeutic potential in hepatocellular carcinoma.

Xu T, Li L, Huang C, Miao CG, Li J.

Hepatol Res. 2014 Jul;44(7):825. doi: 10.1111/hepr.12191. No abstract available.

PMID:
25041492
3.

APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia.

Song X, Li X, Gao J, Zhao J, Li Y, Fan X, Lv L.

PLoS One. 2014 Apr 7;9(4):e93902. doi: 10.1371/journal.pone.0093902. eCollection 2014.

4.

A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment.

Song HT, Sun XY, Zhang L, Zhao L, Guo ZM, Fan HM, Zhong AF, Niu W, Dai YH, Zhang LY, Shi Z, Liu XP, Lu J.

J Psychiatr Res. 2014 Jul;54:134-40. doi: 10.1016/j.jpsychires.2014.03.008. Epub 2014 Mar 20.

PMID:
24694668
5.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;10:CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
6.

Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment.

Ota VK, Noto C, Gadelha A, Santoro ML, Silva PN, Melaragno MI, Smith Mde A, Cordeiro Q, Bressan RA, Belangero SI.

Psychiatry Res. 2013 Dec 30;210(3):1290-2. doi: 10.1016/j.psychres.2013.09.016. Epub 2013 Oct 7.

PMID:
24113126
7.

Targeting the circulating microRNA signature of obesity.

Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M, Gómez-Ambrosi J, Anglada R, Fernández-Formoso JA, Ricart W, Frühbeck G, Fernández-Real JM.

Clin Chem. 2013 May;59(5):781-92. doi: 10.1373/clinchem.2012.195776. Epub 2013 Feb 8.

8.

Association study of NRXN3 polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population.

Hu X, Zhang J, Jin C, Mi W, Wang F, Ma W, Ma C, Yang Y, Li W, Zhang H, Du B, Li K, Liu C, Wang L, Lu T, Zhang H, Lv L, Zhang D, Yue W.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:197-202. doi: 10.1016/j.pnpbp.2012.12.007. Epub 2013 Jan 7.

PMID:
23306218
9.

Comparison of treatment response in second-episode versus first-episode schizophrenia.

Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L.

J Clin Psychopharmacol. 2013 Feb;33(1):80-3. doi: 10.1097/JCP.0b013e31827bfcc1.

PMID:
23277247
10.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
11.

Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.

Scheltema Beduin AA, Swets M, Machielsen M, Korver N; Genetic Risk and Outcome of Psychosis Investigators.

J Clin Psychiatry. 2012 Nov;73(11):1395-402. doi: 10.4088/JCP.11m07164.

PMID:
23218156
12.

Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia.

Miura I, Takeuchi S, Katsumi A, Kanno K, Watanabe K, Mashiko H, Niwa S.

Hum Psychopharmacol. 2012 Sep;27(5):517-20. doi: 10.1002/hup.2251. Epub 2012 Aug 23.

PMID:
22927115
13.

Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.

Novick D, Ascher-Svanum H, Brugnoli R, Bertsch J, Hong J, Haro JM.

J Nerv Ment Dis. 2012 Jul;200(7):637-43. doi: 10.1097/NMD.0b013e31825bfd95.

PMID:
22759944
14.

Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.

Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T.

Psychiatry Clin Neurosci. 2012 Jun;66(4):313-21. doi: 10.1111/j.1440-1819.2012.02351.x.

PMID:
22624736
15.

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.

Barteček R, Juřica J, Zrůstová J, Kašpárek T, Pindurová E, Žourková A.

Neuro Endocrinol Lett. 2012;33(2):236-44.

PMID:
22592207
16.

Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.

Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G.

J Clin Psychiatry. 2012 Apr;73(4):e541-7. doi: 10.4088/JCP.11m07138.

PMID:
22579160
17.

Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance.

Gao S, Hu Z, Cheng J, Zhou W, Xu Y, Xie S, Liu S, Li Z, Guo J, Dong J, Huang M.

Clin Biochem. 2012 Jul;45(10-11):787-92. doi: 10.1016/j.clinbiochem.2012.04.016. Epub 2012 Apr 27.

PMID:
22560999
18.

Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.

Smesny S, Langbein K, Rzanny R, Gussew A, Burmeister HP, Reichenbach JR, Sauer H.

Schizophr Res. 2012 Jul;138(2-3):164-70. doi: 10.1016/j.schres.2012.02.031. Epub 2012 Apr 17.

PMID:
22516552
19.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
20.

Aberrant expression of serum miRNAs in schizophrenia.

Shi W, Du J, Qi Y, Liang G, Wang T, Li S, Xie S, Zeshan B, Xiao Z.

J Psychiatr Res. 2012 Feb;46(2):198-204. doi: 10.1016/j.jpsychires.2011.09.010. Epub 2011 Nov 16.

PMID:
22094284
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk